NDC 50090-7339-01 - Ezetimibe
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-7339
- Requested NDC
- 50090-7339-01
- Package NDCs from labels
- 50090-7339-0, 50090-7339-1, 50090-7339-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2024-10-21
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Ezetimibe - A-S Medication Solutions | A-S Medication Solutions | 2024-10-21 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-7339-0 | Ezetimibe | 30 in 1 BOTTLE | TABLET | 30 | 1 | |
| 50090-7339-1 | Ezetimibe | 90 in 1 BOTTLE | TABLET | 90 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-7339 | EZETIMIBE TABLET [A-S MEDICATION SOLUTIONS] | 1 | Current NDC, 2 package rows | 20241023_5877150f-2807-435e-8e5b-a07dc7dbfd27.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-7339-0 | EA - Each | 50090-7339 | 3c9f6bf5-fc01-48cd-956a-a64eb94afe2d | 1 | 2024-11-05 |
| 50090-7339-1 | EA - Each | 50090-7339 | 4a0bfdb3-7e11-4cdb-a8e8-25ae48534ed2 | 1 | 2024-11-05 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ezetimibe | EZETIMIBE | Bryant Ranch Prepack | d6b4fd12-9954-42ba-b42a-56f3747c47ff | 2024-07-09 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Artificial Tears | POLYVINYL ALCOHOL, POVIDONE | NuCare Pharmaceuticals,Inc. | 9c1c4911-908e-3c3c-e053-2995a90abcfc | 2024-06-14 | Warnings | FZ989GH94E |
| Ezetimibe | EZETIMIBE | ScieGen Pharmaceuticals Inc | 11de499b-ad8a-46a6-9021-c8eba72ae414 | 2024-06-12 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Ezetimibe | EZETIMIBE | Macleods Pharmaceuticals Limited | ebe3fa4e-82c4-4a9a-9aec-f64019391f4e | 2024-05-13 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Enviroclenz | BERBERIS VULGARIS, CARDUUS MARIANUS, CHELIDONIUM MAJUS, GLYCYRRHIZA GLABRA, LAPPA MAJOR, RHAMNUS FRANGULA, STILLINGIA SYLVATICA, TARAXACUM OFFICINALE, TRIFOLIUM PRATENSE, GERMANIUM SESQUIOXIDE, PHYTOLACCA DECANDRA, ACETONE, AMMONIUM MURIATICUM, BENZINUM, PROPYLENE GLYCOL, SODIUM LAURYL SULFATE, SODIUM TRIPOLYPHOSPHATE, TEREBINTHINA, METHANOL, CHLORINUM, IRIDIUM METALLICUM, LYCOPODIUM CLAVATUM, NITRICUM ACIDUM, NUX VOMICA, PHOSPHORICUM ACIDUM | Deseret Biologicals, Inc. | 92816bbe-96d6-45fc-9929-d3e6df394a33 | 2024-05-02 | Warnings | 368GB5141J |
| ezetimibe and simvastatin | EZETIMIBE AND SIMVASTATIN | Glenmark Pharmaceuticals Inc., USA | 32d0e130-1211-44ca-be60-5379ffec96fd | 2024-04-30 | Warnings, Adverse reactions | EOR26LQQ24 |
| Ezetimibe | EZETIMIBE | Orient Pharma Co., Ltd. | b6e77d9b-a553-63e0-e053-2a95a90a18fe | 2024-04-15 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Ezetimibe | EZETIMIBE | Bryant Ranch Prepack | 11828685-dc27-42d8-a6ff-f110018207d1 | 2024-04-04 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Ezetimibe | EZETIMIBE | Bryant Ranch Prepack | 03609879-bad2-4e75-83fe-1e1a2fd300c3 | 2024-04-03 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Clear Eyes Natural Tears | POLYVINYL ALCOHOL AND POVIDONE | Prestige Brands Holdings, Inc. | efba3eb0-798d-4635-b19b-4970e45b3cc9 | 2024-04-01 | Warnings | FZ989GH94E |
| Envirotox | TRITICUM AESTIVUM, BERBERIS VULGARIS, LAPPA MAJOR, RHAMNUS PURSHIANA, SENNS (CASSIA ANGUSTIFOLIA), PHYTOLACCA DECANDRA, GLYCYRRHIZA GLABRA, STILLINGIA SYLVATICA, TRIFOLIUM PRATENSE, XANTHOXYLUM FRAXINEUM, ACETONUM ACETONE, SODIUM TRIPOLYPHOSPHATE, PROPYLENE GLYCOL, BENZINUM, AMMONIUM MURIATICUM, SODIUM LAURYL SULFATE, TEREBINTHINA, BELLADONNA, LYCOPODIUM CLAVATUM, NITRICUM ACIDUM, NUX VOMICA, PHOSPHORICUM ACIDUM, BELLADONNA, LYCOPODIUM CLAVATUM, NITRICUM ACIDUM, NUX VOMICA, PHOSPHORICUM ACIDUM. | BioActive Nutritional, Inc. | 2b5cfdba-cf4d-4eb0-8c60-20eac6922663 | 2024-03-26 | Warnings | 368GB5141J |
| Ezetimibe | EZETIMIBE | Golden State Medical Supply, Inc. | 4a78aa8d-1fe0-4df0-a15b-2350c15aead1 | 2024-03-25 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| ezetimibe | EZETIMIBE | Quallent Pharmaceuticals Health LLC | 68247ce8-e812-42f2-a3ba-0f6e49acca63 | 2024-03-20 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| REFRESH CLASSIC | POLYVINYL ALCOHOL, POVIDONE | A-S Medication Solutions | 3bf6193c-56db-45ad-844c-58eb8c33cba9 | 2024-03-14 | Warnings | FZ989GH94E |
| Ezetimibe | EZETIMIBE | Ohm Laboratories Inc. | 5b3842f6-c80a-47b8-8a82-b69e465b05f7 | 2024-03-05 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| ezetimibe | EZETIMIBE | Zydus Pharmaceuticals USA Inc. | f852b12f-e25f-415b-b1e2-58955d609507 | 2024-02-27 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| Ezetimibe | EZETIMIBE | A-S Medication Solutions | 57d19491-cba1-4720-b69d-481574459201 | 2024-02-22 | Warnings, Adverse reactions | 349556 EOR26LQQ24 |
| GOODSENSE ARTIFICIAL TEARS | POLYVINYL ALCOHOL | Proficient Rx LP | f29c792c-6cb2-449f-b97d-6304a58dec2a | 2024-02-01 | Warnings | FZ989GH94E |
| GoodSense Artifical Tears | POLYVINYL ALCOHOL, AND POVIDONE | Proficient Rx LP | cd24da78-fd90-4a9c-8e5f-f7fc56ec0fc9 | 2024-02-01 | Warnings | FZ989GH94E |
| ezetimibe and simvastatin | EZETIMIBE AND SIMVASTATIN | A-S Medication Solutions | 2c936363-b483-46c6-936c-a07d8ab0280c | 2024-01-16 | Warnings, Adverse reactions | EOR26LQQ24 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.